Hou et al. (2017). further demonstrated that SPRY3 and GSK3 expression correlates with clinical resistance to the FLT3-inhibitor Quizartinib in primary human AML samples, and inhibition of their downstream pathways re-sensitizes AML cells to Quizartinib in vitro. Here, FLT3 is linked to acute myeloid leukemia.